Full Data For Seattle Genetics' Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates
This article was originally published in The Pink Sheet Daily
Executive Summary
Pivotal trial data look good for soon-to-be-filed orphan lymphoma candidate, partnered with Takeda. SGN-35 may be among the first conjugates to hit the U.S. market, with launch projected for third quarter 2011.
You may also be interested in...
Seattle Genetics Files Antibody-Drug Conjugate BLA; Late August Approval Possible
The company released impressive data for SGN-35 against two advanced lymphomas in December, giving the drug a good chance at a six-month approval based on unmet need.
Seattle Genetics Files Antibody-Drug Conjugate BLA; Late August Approval Possible
The company released impressive data for SGN-35 against two advanced lymphomas in December, giving the drug a good chance at a six-month approval based on unmet need.
ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie
The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.